MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study

Endogenous Cushing’s syndrome (CS) is a rare, serious disorder caused by chronically elevated cortisol. A phase 3, open-label study (SONICS) of levoketoconazole in adults with CS and mean urinary free cortisol (mUFC) ≥1.5 × upper limit of normal (ULN) at baseline demonstrated normalization of mUFC i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Zacharieva, Sabina Z, Pivonello, Rosario, Elenkova, Atanaska, Tóth, Miklós, Shimon, Ilan, Stigliano, Antonio, Badiu, Corin P, Brue, Thierry, Georgescu, Carmen Emanuela, Cohen, Fredric J, Fleseriu, Maria
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Neuroendocrinology and Pituitary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208150/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1129
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars